NT5E and non-small cell lung carcinoma: Additionally in NSCLC, Durvalumab, a PD-L1 antibody, is currently being tested in combination with Oleclumab, a CD73 blocking antibody, or Monalizumab, an antibody blocking inhibitory NK cell receptor NKG2A, with promising phase II results leading to the initiation of a phase III trial (2).